Transgene Biotek share news and announcements
BSE: 526139Healthcare ServicesSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹2.37.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹19 Cr4,238th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 2.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- −17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- −2.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 2.05
- Volume, BSEVolume. Shares traded on the last trading day.
- 26,565
Transgene Biotek share news and announcements
482 announcements, routine notices left out, newest first. Page 3 of 10.
Feb 2024
14 Feb · Results
Jan 2024
29 Jan · Board meeting
Meeting on 14 Feb 2024: quarterly results9 Jan · Business
Dec 2023
1 Dec · Meeting
Nov 2023
14 Nov · Results
14 Nov · Board meeting
6 Nov · Board meeting
Meeting on 14 Nov 2023: quarterly results
Oct 2023
8 Oct · Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 30Th September 2023
Aug 2023
Jul 2023
17 Jul · Board meeting
Meeting on 5 Aug 2023: quarterly results
May 2023
12 May · Board meeting
Meeting on 30 May 2023: audited results12 May · Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Year Ended On 31St March 2023.
Apr 2023
28 Apr · Setting-Up Of A New Facility For Biologics And Their Formulations - Phase I.
7 Apr · Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Feb 2023
Jan 2023
27 Jan · Board meeting
Meeting on 14 Feb 2023: quarterly results
Dec 2022
20 Dec · Business
Nov 2022
4 Nov · Board meeting
Meeting on 12 Nov 2022: quarterly results
Oct 2022
7 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 01 Oct · Meeting
1 Oct · Meeting
Sep 2022
2 Sep · Reg. 34 (1) Annual Report.
Aug 2022
Jul 2022
20 Jul · Board meeting
Meeting on 13 Aug 2022: quarterly results and annual general meeting1 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2022